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Abstract 
Although its prevention and treatment has progressed significantly since HIV’s first known case of 
human infection in 19591, with a worldwide prevalence of 36.9 million and incidence of 2.0 million in the 
year 2014 alone there remains significant room for improvement. Along with this persistence of 
infection comes an ongoing drive for better preventative measures. The current pre-exposure 
prophylaxis (PrEP) method available, once daily oral Truvada, exhibits variable efficacy due to 
differences in individual patient absorption and mandates consistent patient utilization for prevention of 
infection.2 This project aims to improve upon these PrEP methods by providing a long acting injectable 
for the introduction of one or more antiretrovirals (ARVs) prior to the exposure for the prevention of 
infection in such an event. 
The following is a description of a subcutaneous injection which will introduce an in-situ forming implant 
(ISFI) allowing the prolonged release of drug through diffusion from and degradation of the resulting 
solid depot. Our goal is to achieve plasma drug concentration/s in appropriate animal models greater 
than or equal to four times the IC90 of each drug for at least three months. Also, we would like to 
ultimately demonstrate that the subcutaneous route of ISFI administration will allow for emergency 
removal of the system if needed. This promotes safety above the currently offered oral PrEP method as 
well as the intramuscular nanopartical suspension based injections currently in phase II clinical trials.3  
 
Introduction 
According to the CDC, there are currently more than 1.2 million people in the United States that are at 
high enough risk for HIV infection to warrant daily oral pre-exposure prophylaxis (PrEP). Unfortunately, 
most of these individuals are not receiving treatment contributing to the around 40,000 yearly new HIV 
diagnoses in the US. A primary obstacle to use is knowledge of PrEP availability. Since its approval in 
2012, oral Truvada has been widely used for the prevention of HIV infection upon exposure, however, 
according to the CDC only about one third of primary care physicians and nurses are aware of PrEP for 
HIV prevention.4 When Truvada is implemented, variability in adherence and absorption results in a 
wide range of efficacy ranging from 0% to 75% in six clinical trials during the time period from 2010 
through 2015.5 There is a widely accepted correlation between adherence and efficacy of PrEP for HIV. 
Even small variations in administration can result in a significant effect on disease contraction upon 
exposure. Overall adherence has been shown to range from 21 to 86% with the latter resulting in a 96% 
reduction in incidence of infection and efficacy decreasing with decreasing usage.5  
There are many barriers to adherence when it comes to HIV PrEP. Patients may have trouble 
remembering to take daily oral regimens. Also, other methods currently undergoing investigation may 
require the application of a gel, cream, or foam at the time of sexual intercourse which may interfere 
with the act itself and discourage its use. A long acting (LA) injectable, such as the one presented here, 
would eliminate the need for daily adherence and is concealed with the actual administration far 
enough removed from the act to avoid any interference. To date there are no systemic LA formulations 
approved for HIV PrEP. There are, however, two LA injectables in phase 2 clinical trials: TMC 278-LA a 
rilpivirine (RPV) based system and GSK 744-LA a cabotegravir (CAB) based system. These products, 
however, are not without limitation. Both are nanoparticle preparations which require the milling of 
drug to micron size and the application of a surfactant coating to produce stable suspensions for 
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intramuscular injection. Their intramuscular administration and suspension based nature of their 
formulation will not allow for their removal in the event of an adverse reaction. Also, the nanocrystal 
approach has not proven flexible enough to accommodate two or more drugs at this time. HIV has 
proven to be a highly resistant virus which is prone to mutation, the treatment and prevention of which 
requires a multidrug regimen. Any inability to formulate multiple drugs into a prophylactic system 
presents a large disadvantage. 
A simple formulation which can accommodate multiple antiretrovirals and allow the removal of the drug 
release system in the event of an adverse reaction is much needed. We intend to provide an in situ 
forming implant (ISFI) injection based on a simple formulation of a polymer and biocompatible solvent 
into which drug is added as easily as a solution is made. The system will be introduced subcutaneously 
and solidify into a depot upon contact with the aqueous environment. This method of administration 
permits the surgical removal of the depot should any adverse reaction occur. It can also easily 
accommodate multiple antiretrovirals with the potential to deliver at least 4 times the IC90 of each 
antiretroviral for at least 30 days following injection providing long term protection against infection in 
the event of HIV exposure. The portion of the project described in this paper pertains to the production 
of various ISFI formulations, the characterization of these ISFI formulations (including stability and drug 
saturated concentration) and their in vitro release of drug over time. 
 
Methods 
Formulation  
Depots were prepared at varying concentrations of drug in various ratios of polymer to solvent. All are 
based on the dissolution of polylactide-co-glycolide (PLGA) in N-methyl-2-pyrrolidone (NMP). PLGA to 
NMP mass ratios of 1:2, 1:4, 1:8, and 1:16 were investigated with the addition of one of three 
antiretrovirals: MK-2048, dolugetravir (DTG), or rilpivirine (RPV). To prepare the ISFIs, an appropriate 
mass of NMP was added to a 10 mL scintillation vial followed by an appropriate mass of PLGA 
(depending on the mass ratio desired). Dissolution of the polymer was then assisted with immediate 
vortexing followed by 5 minutes in a sonicating water bath at 40oC. Subsequent vortexing and 40oC 
water bath sonication was performed as needed until complete dissolution is achieved. The desired 
amount of drug was then added to the formulation with vortexing followed by sonication in a 40oC 
water bath which was repeated again as often as needed until drug was completely dissolved. 
 
Density and Stability 
The density of various formulations with and without drug were determined and noted (Tables 1-3). 
Stability of various formulations and various concentration of drug was tested at both room 
temperature and 4oC. For stability testing formulations were prepared at various drug concentrations 
and PLGA/NMP (w/w) ratio then kept at constant room temperature or 4oC while in 10 mL scintillation 
vials wrapped in aluminum foil to protect from light. They were then observed over time for 
precipitation of drug to occur (Table 4). 
 
In-vitro Release 
The ISFI system has a release characterized by an initial burst of drug release, followed by a period of 
diffusion, and finally polymer degradation and erosion. In-vitro experiments were used as an initial 
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investigation into the profile of this release. Drug depots were injected into 200 mL of medium and kept 
at 37oC. One mL aliquots of medium were removed over time. Prior to sampling, the medium was mixed 
by pulling up and releasing with the 1 mL pipettor 3 times before keeping the 4th mL as a sample. 1 mL of 
fresh medium was then added to the sample jar. Experiments are done in triplicate (n=3) for each drug. 
All experiments are kept at 37o C. Resulting samples were analyzed using HPLC UV/Visible 
spectrophotometry to determine the analytical amount of drug released over time. Media 
experimented with included 0.01 M phosphate buffered saline (PBS) with 2% (w/w) solutol adjusted to a 
pH of 7.0, 0.01 M PBS with 2% Tween 80 (w/w) adjusted to a pH of 7.0, 25% (w/w) liquid PEG 400 in 0.10 
M PBS adjusted to a pH of 7.0, and 50% IPA and water (Figures 1-11). 
 
The influence of the use of a foam support as a skin tissue simulant on the release of drug from an ISFI 
system was investigated (Figure 10). Using a 20 gauge 1 inch long needle fitted to a 20 µL pipettor set at 
20.00 µL, depot was injected into the center of a pre-cut and pre-wetted 1 cm3 cut from polytech foam. 
The foam cube was wetted by repeatedly squeezing the foam cube with flat tip forceps while 
submerging it into the release medium (0.01 M phosphate buffered saline with 2% solutol, pH 7.4) until 
air was no longer released upon squeezing. Prior to pulling depot solution from sample vial, the pipettor 
was pushed to the second stop to obtain greater suction. Injection was done just outside of the release 
medium jar with the ISFI containing foam them immediately dropped into the jar. Time was started as 
soon as the depot containing foam was placed into the release medium and the first sample was taken 
at t = 0. One milliliter samples were removed from medium at intervals throughout a 35 day period 
using the same sampling method as described above followed by the same subsequent analysis. 
 
Results 
 
Table 1: Saturated DTG depot: 
Placebo formulation 
PLGA/NMP (w/w) 
Density (g/mL) DTG (mg) in ISFI Conc % (w/w) Conc (mg/mL) 
1:2 1.1132 208.0 8.2022 91.304 
1:4 1.0933 265.6 11.205 122.50 
1:8 1.0911 331.1 15.605 170.27 
1:16 1.0768 387.1 18.979 204.38 
 
Table 2: Saturated RPV depot: 
Placebo formulation 
PLGA/NMP (w/w) 
Density (g/mL) RPV (mg) in ISFI Conc % (w/w) Conc (mg/mL) 
1:2 1.1203 146.36 9.6586 108.21 
1:4 1.0705 165.20 9.8187 105.11 
1:8 1.0494 155.24 9.3848 98.484 
1:16  1.0257 151.89 9.8187 100.71 
 
Table 3: Placebo formulations: 
Placebo formulation 
PLGA/NMP (w/w) 
Density (g/mL) 
1:4  1.0720 
1:8  1.0379 
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Table 4: Stability: 
Formulation Date Initiated Room 
Temperature 
(RT): Date of 
precipitation 
4oC: Date of 
precipitation 
Days in 
solution (RT) 
Days in 
solution 
(4oC) 
DTG: 9.0909 % in 
1:2 (w/w) 
7/17/14 9/21/14 7/20/14 66 3 
DTG: 6.994% 
(w/w) in 1:2 
PLGA/NMP 
12/15/14 2/14/15 12/19/14 61 4 
DTG: 5.997 % in 
1:2 (w/w) 
8/5/14 None as of 
11/2/15 
9/14/14 >1 yr 21 
RPV: 4.842 % 
(w/w) in 1:2 
PLGA/NMP 
2/16/15 None as of 
11/2/15 
6/2/15 > 8 mo 107 
SATURATED 
SOLNS 
     
DTG: 11.205 % 
(w/w) in 1:4 
PLGA/NMP 
7/16/15 7/23/15 7/17/15 7 1 
DTG: 15.605 % 
(w/w) in 1:8 
PLGA/NMP 
7/16/15 7/23/15 7/17/15 7 1 
DTG: 18.979 % 
(w/w) in 1:16 
PLGA/NMP 
10/9/15 None as of 
12/15/15 
10/10/15 67+ 
(last observed 
12/15/15)  
1 
RPV: 9.659 % 
(w/w) in 1:2 
PLGA/NMP 
10/15/15 10/28/15 10/16/15 13 1 
RPV: 9.819 % 
(w/w) in 1:4 
PLGA/NMP 
10/20/15 12/15/15 10/21/15 56 1 
RPV: 9.385 % 
(w/w) in 1:8 
PLGA/NMP 
10/20/15 11/1/15 10/21/15 12 1 
RPV: 9.066 % 
(w/w) in 1:16 
PLGA/NMP 
10/15/15 10/21/15 10/16/15 6 1 
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Figure 1 (above): Cumulative % drug release over time from 0.8:1:2 (w/w/w) MK-2048/PLGA/NMP ISFI 
by in 200 mL 0.01 M PBS with 2% solutol at pH 7.0 and 37oC. 
 
 
 
Figure 2 (above): Cumulative percent drug release over time from 9:1:30 (w/w/w) MK-2048/PLGA/NMP 
ISFI by in 200 mL 0.01 M PBS with 2% solutol at pH 7.0 and 37oC. 
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Figure 3 (above): Cumulative percent drug release over time from 9:1:30 (w/w/w) MK-2048/PLGA/NMP 
ISFI in 200 mL 2% Tween 80 in 0.01 M PBS at pH 7.0 and 37oC.  
 
 
 
Figure 4 (above): Cumulative percent drug release over time from 0.2:1:2 (w/w/w) DTG/PLGA/NMP ISFI 
by in 200 mL 0.01 M PBS with 2% solutol at pH 7.0 and 37oC. 
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Figure 5 (above): Cumulative percent drug release over time from 0.2:1:2 (w/w/w) DTG/PLGA/NMP ISFI 
in 200 mL of 25% (w/w) liquid PEG 400 in 0.01 M PBS at pH 7.0 and 37oC. 
 
 
 
 
Figure 6 (above): Cumulative percent drug release over time from 0.2:1:2 (w/w/w) DTG/PLGA/NMP ISFI 
in 200 mL of 50% IPA/H2O at 37oC. 
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Figure 7 (above): Cumulative concentration of release (mcg/mL) of DTG over time from saturated ISFIs 
of various PLGA/NMP (w/w) ratios (1:2, 1:4, 1:8, and 1:16) in 0.01 M PBS with 2% solutol at pH 7.0 and 
37oC. 
 
 
 
 
 
Figure 8 (above): Cumulative percent release of DTG over time from saturated ISFIs of various 
PLGA/NMP (w/w) ratios (1:2, 1:4, 1:8, and 1:16) in 0.01 M PBS with 2% solutol at pH 7.0 and 37oC. 
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Formulation 
PLGA:NMP 
(w/w) 
Average DTG 
Concentration at 
10 days (mcg/mL) 
Multiplicative 
comparator of release 
to previous formulation 
at 10 days (mcg/mL) 
Average % 
DTG 
Release at 
10 days 
Multiplicative 
comparator of release  
to previous formulation 
(%) at 10 days 
1:2 1.195 NA 1.307 NA 
1:4 2.310 1.933 x [1:2] 3.598 2.752 x [1:2] 
1:8 5.911 2.559 x [1:4] 8.241 2.290 x [1:4] 
1:16 12.803 2.166 x [1:16] 16.341 1.983 x [1:8] 
 
Table 5 (above): A comparison of the average concentration of DTG in release medium for various 
PLGA:NMP (w/w) formulations saturated with DTG (Table 1 and Figures 7-8). 
 
PLGA:NMP 
(w/w) 
Multiplicative 
comparator of release 
to previous formulation 
at 10 days (mcg/mL) 
Explanation of 
"multiplicative 
comparator" (mcg/mL)  
SD from 2 
(representitive of a 
relative doubling) 
Average SD 
from 2  of 
comparators 
1:4 1.9330 [1:4] = 1.9330 x [1:2] 0.0474 0.1867 
1:8 2.5590 [1:8] = 2.5590 x [1:4] 0.3953   
1:16 2.1660 [1:16] = 2.1660 x [1:8] 0.1174   
 
Table 6 (above): The influence of doubling of the mass of NMP relative to PLGA mass in the ISFI of 
saturated DTG formulations on the average concentration of DTG in release medium by multiplicative 
comparator (Table 1 and Figures 7-8). 
 
 
PLGA:NMP 
(w/w) 
Multiplicative 
comparator of release to 
previous formulation at 
10 days (%) 
Explanation of 
"multiplicative 
comparator" (%)  
SD from 2 
(representative of a 
relative doubling) 
Average SD 
from 2 of 
comparators 
1:4 2.7520 [1:4] = 2.7520 x [1:2] 0.5317 0.2496 
1:8 2.2900 [1:8] = 2.2900 x [1:4] 0.2051   
1:16 1.9830 [1:16] = 1.9830 x [1:8] 0.0120   
 
Table 7 (above): The influence of doubling of the mass of NMP relative to PLGA mass in the ISFI of 
saturated DTG formulations on the average % release of DTG in medium relative to total mass of DTG 
present in ISFI by multiplicative comparator (Table 1 and Figures 7-8). 
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Figure 9 (above): Cumulative percent drug release over time from 0.2:1:2 (w/w/w) RPV/PLGA/NMP ISFI 
by in 200 mL 0.01 M PBS with 2% solutol at pH 7.0 and 37oC. (note: standard deviations are too small for 
error bars to be visible beyond data points) 
 
 
 
 
Figure 10 (above): Cumulative percent drug release over time from 0.2:1:2 (w/w/w) RPV/PLGA/NMP ISFI 
suspended in foam support by in 200 mL 0.01 M PBS with 2% solutol at pH 7.0 and 37oC. (note: standard 
deviations are too small for error bars to be visible beyond data points) 
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Figure 11 (above): Cumulative percent drug release over time from 0.8:1:2 (w/w/w) RPV/PLGA/NMP ISFI 
in 200 mL of 50% IPA/H2O at 37oC. 
 
 
Conclusions and Discussion 
 
All saturated solutions of drug in ISFI (prepared at room temperature) precipitated within 24 hours at 
4oC, as would be expected (Table 4). For unsaturated solutions, length of stability of DTG dissolved in 
ISFI (1:2 mass ration of PLGA:NMP) increased with decreasing DTG concentration at both room 
temperature and 4oC, with the exception of 9.0909% versus 6.994% at room temperature which 
precipitated at 66 and 61 days respectively. All unsaturated and saturated solutions for both DTG and 
RPV in ISFI remained in solution for a greater length of time when kept at room temperature versus 4oC 
(Table 4). This combined with the non-aqueous nature of all formulations indicate that room 
temperature is a superior, safe, and preferred storage condition. 
 
Figure 1 and Figure 2 demonstrate that increasing the relative amount of MK-2048 in the formulation 
while decreasing the relative amount of PLGA to NMP will result in a faster and overall much more 
complete release of MK-2048 from ISFI (> 99% versus < 5% at 5 days). Although results which were 
comparable to that of 2% solutol in 0.1 M PBS were initially observed, further experimentation with 2% 
(w/w) Tween 80 in 0.01 M PBS (formulation used in Figure 3) produced inconsistent and unpredictable 
data. It was also found that DTG release from 1:2 (w/w) PLGA/NMP ISFI into 50% (w/w) IPA/H2O 
demonstrated an incomplete release of drug with a profile resembling saturation at 2 days (Figure 6). 
RPV release from the same ISFI formulation into the same medium, however, produced complete 
release at 63 days with a desirable profile (Figure 11). As for experimentation with foam support as a 
skin simulant, Release profiles for 0.2:1:2 RPV in 200 mL of 2% (w/w) solutol in 0.1 M PBS for free 
release ISFI and foam supported ISFI were very similar (Figure 9-10). Both achieved 20% release within 
30 days (between days 25 to 30). 
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Of the various media formulations, 2% solutol (w/w) in 0.1 M PBS produced the most favorable and 
consistent results for DTG release (Figures 4-6) when compared to 0.01 M PBS with 2% Tween 80 (w/w), 
25% (w/w) liquid PEG 400 in 0.10 M PBS, and 50% IPA and water. As a result of these findings, a 2% 
solutol (w/w) in 0.1 M PBS medium was used in the subsequent experiments performed to analyze the 
effects of varying the mass of PLGA present relative to NMP in a DTG containing ISFI (Table 1; Figure 7-
8). Following this investigation, a trend was observable in the comparison of 1:2, 1:4, 1:8, and 1:16 
PLGA:NMP (w/w) formulations of saturated DTG ISFIs. There was a relative doubling of both cumulative 
drug concentration and % drug release compared to total drug in depot at 10 days following ISFI release 
into medium with each doubling of the mass of NMP used relative to the mass of PLGA used in the ISFI 
formulation. There was an average standard deviation of 0.2 from a multiplicative comparator of 2 
(Table 5 and Table 6) for each corresponding doubling of NMP mass relative to PLGA. This same 
standard deviation of 0.2 from an exact doubling is apparent in both the average concentration versus 
time data (Figure 7 and Table 5) as well as the average % drug release relative to the total drug present 
in each depot data (Figure 8 and Table 6). The presence of the trend in the latter experiment (Figure 8) 
demonstrates its conservation even with the normalization of drug release based on the concentration 
of drug in depot. This corrects for the variability in the saturation concentrations of DTG for each 
PLGA:NMP (w/w) formulation (Table 1).  
 
 
Future Plans 
There is much investigation required in preparation for clinical trials. Future investigative plans include 
the Scanning Electron Microscopy analysis of in vitro depot degradation. Also, the pharmacokinetics of 
DTG release from ISFI in non-human primate models will be assessed. In preparation for multi-drug 
containing ISFIs in order to provide effective prophylaxis from HIV’s ability to readily mutate, the In vivo 
efficacy of DTG/RPV combination ISFI in BLT mouse model should be determined. Optimization of ISFI to 
accommodate drug concentrations for human dosing will also be required for feasibility of providing 
serum concentrations that can protect against infection of HIV in the event of exposure. 
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